27 Mar 2017 10:30
Sinclair Pharma plc
Appointment of Joint Broker
London, 27 March 2017 Sinclair Pharma plc (SPH.L), ("Sinclair") the international Aesthetics company, announces the appointment of RBC Capital Markets to act as its joint broker alongside Peel Hunt LLP, with immediate effect.
For further information please contact:
Sinclair Pharma plc | Tel: +44 (0) 20 7467 6920 |
Chris Spooner Alan Olby Andy Crane |
Peel Hunt LLP (NOMAD and Joint Broker) | Tel: +44 (0) 20 7418 8900 |
James Steel Oliver Jackson |
RBC Capital Markets (Joint Broker) | Tel: +44 (0) 20 7653 4000 |
Marcus Jackson Laura White |
Media enquiries
FTI Consulting | Tel: +44 (0) 203 727 1000 |
Ben Atwell Brett Pollard Stephanie Cuthbert |
Notes to Editors:
About Sinclair Pharma plc
Sinclair Pharma plc is an international company operating in the fast growth, high gross margin, global aesthetics market. Sinclair has built a strong portfolio of differentiated, complementary aesthetics technologies, which are experiencing significant growth, targeting unmet clinical needs for effective, high quality, longer duration, natural looking and minimally-invasive treatments. The Company is planning entry to multiple new geographic markets and line extension launches over the next few years. Sinclair has an established sales and marketing presence in the leading EU markets and Brazil, and a network of international distributors.
For more information, please visit
www.sinclairpharma.com
Sinclair Pharma (SPH)